GlassScriptPhysician profile
Nichole Ford
NPI 1760943310
$6,294.51
in general payments reported to CMS, 2019-2025
27 companies · $2,136 in 2025
The $2,136 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.72 · 2021: $22.18 · 2023: $1,700 · 2024: $2,421 · 2025: $2,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,168 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,167.61 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,026.10 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $894.88 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $647.19 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $621.27 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $464.63 | 2023-2025 | |
| Lilly USA, LLC | $435.23 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $371.31 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $321.06 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $283.67 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $279.16 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $171.50 | 2024-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $165.41 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Exact Sciences Corporation | $117.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $76.40 | 2024-2025 | Rexulti, Vyepti |
| Amgen INC. | $71.76 | 2023-2025 | Repatha, Prolia, Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $63.43 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.65 | 2023-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.04 | 2023-2024 | Jardiance |
| Dexcom, INC. | $40.34 | 2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $33.31 | 2025 | Qutenza |
| Sanofi-Aventis U.S. LLC | $16.06 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.51 | 2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $14.96 | 2024 | Xarelto |
| Azurity Pharmaceuticals, INC. | $14.93 | 2023 | Edarbi |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2023 | Trintellix |
| Merck Sharp & Dohme LLC | $14.72 | 2019 | |
| Mylan Specialty L.P. | $13.75 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.